RAJI

RAJI (Burkitt’s Lymphoma CDX Model) 

The RAJI line was derived from a patient with Burkitt’s lymphoma. It is Epstein–Barr virus (EBV)-positive, reflecting a clinically relevant subset of this cancer. RAJI has been a standard B-cell lymphoma model in hematology research. Its reproducibility makes it valuable for translational pipelines. 

Key Features: 

• Derived from Burkitt’s lymphoma. 

• EBV-positive B-cell line. 

• Strong growth in xenograft systems. 

• Suitable for lymphoma drug research. 

Applications: 
RAJI is used in studies of B-cell lymphoma biology and EBV-associated oncogenesis. Researchers apply it in testing cytotoxic and targeted therapies. It supports biomarker and immunotherapy research in Burkitt’s lymphoma. Its stability ensures consistency in hematology pipelines.